稳定型冠状动脉综合征的外科血运重建:ISCHEMIA试验与单中心匹配人群的真实世界分析
本研究将353例符合ISCHEMIA入选标准并接受外科血运重建的慢性冠状动脉综合征患者与ISCHEMIA试验人群比较,评估心血管事件或死亡风险。5年主要复合终点累积风险为11%,低于ISCHEMIA保守组的18%和血运重建组的16%(P<0.001);5年心肌梗死风险为7%,低于试验保守组的12%和侵入组的10%(P<0.001)。作者认为ISCHEMIA试验结果不能直接迁移至真实世界场景,个体化治疗策略(尤其合并糖尿病和左心室功能减退者)可获得最佳结果。
要点
- 5年主要复合终点累积风险在外科患者为11%,ISCHEMIA保守组18%、血运重建组16%(P<0.001)。
- 5年心肌梗死风险在外科患者为7%,ISCHEMIA保守组12%、侵入组10%(P<0.001)。
- 作者认为ISCHEMIA试验结果不能直接迁移至真实世界场景,个体化治疗策略可获得最佳结果。
核心结论
- 慢性冠状动脉综合征外科血运重建患者的长期结果显示,ISCHEMIA试验结果不能直接迁移至真实世界场景,且未改变既往医疗实践。
- 作者认为个体化治疗策略,尤其对合并糖尿病和左心室功能减退的患者,可获得最佳结果。
研究设计与样本
- 单中心匹配人群的真实世界分析,纳入353例接受外科血运重建且符合ISCHEMIA入选标准的慢性冠状动脉综合征患者。
- 入选条件为功能学检查发现心肌缺血且血管造影发现冠状动脉疾病。
- 主要终点为心血管死亡、心肌梗死、因不稳定型心绞痛再住院、心力衰竭和复苏后心脏骤停的复合终点;次要终点为全因死亡、心血管死亡、心肌梗死和再住院。
主要发现
- 353例患者中62例(17.6%)发生主要终点事件。
- 无事件累积生存率在6个月为97%,1年为96%,5年为89%,10年为80%。
- 5年主要复合终点累积风险在外科患者为11%,ISCHEMIA保守组为18%,ISCHEMIA血运重建组为16%(P<0.001)。
- 5年心肌梗死风险在外科患者为7%,ISCHEMIA保守组为12%,ISCHEMIA侵入组为10%(P<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to test if the current general practice of surgical revascularization is comparable to the setting of International Study of Comparative Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial and to evaluate the comparative risk of cardiovascular events or death after coronary artery bypass grafting. METHODS: We selected patients undergoing surgical revascularization and matching ISCHEMIA inclusion criteria. Chronic coronary syndrome patients were included if diagnosis of myocardial ischaemia by functional testing and coronary artery disease at angiography were detected. The primary end point was a composite of cardiovascular death, myocardial infarction, rehospitalization for unstable angina, heart failure and resuscitated cardiac arrest. Secondary end points were death by any cause, cardiovascular death, myocardial infarction and rehospitalization. RESULTS: Among 353 patients, the primary outcome occurred in 62 (17.6%) patients. At 6 months, cumulative event-free survival was 97%, at 1 year 96%, at 5 years 89% and at 10 years 80%. Cumulative risk of the primary composite outcome at 5 years was 11%, 18% in the conservative arm of ISCHEMIA and 16% in the revascularization arm of ISCHEMIA (P < 0.001). Risk of myocardial infarction at 5 years was 7% in surgical patients and 12% and 10% in the conservative and invasive arms of the trial, respectively (P < 0.001). CONCLUSIONS: Long-term results in surgical patients treated for chronic coronary syndromes showed that ISCHEMIA trial findings are not transferable in a 'real-world' scenario and have not changed previous medical practice. A patient-tailored approach, especially with diabetes and reduced left ventricle function, offers the best results in patients with stable coronary artery disease.
引用
- De Martino A, Del Re F, Gregori D, et al. Surgical revascularization for stable coronary syndrome: the ISCHEMIA trial versus a single-centre matched population-a real-world analysis of patients undergoing surgical revascularization. Eur J Cardiothorac Surg. 2022. PMID: 35143617. doi:10.1093/ejcts/ezac068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。